[Federal Register Volume 61, Number 88 (Monday, May 6, 1996)]
[Notices]
[Pages 20275-20276]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-11217]



-----------------------------------------------------------------------


DEPARTMENT OF JUSTICE

Importation of Controlled Substances; Notice of Application

    Pursuant to Section 1008 of the Controlled Substances Import and 
Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in Schedule I or II and prior to issuing a 
regulation under Section 1002(a) authorizing the importation of such a 
substance, provide manufacturers holding registrations for the bulk 
manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with Section 1311.42 of Title 21, Code of 
Federal Regulations (CFR), notice is hereby given that on March 27, 
1996, Research Biochemicals, Limited Partnership, Attn: Richard Milius, 
1-3 Strathmore Road, Natick, Massachusetts 01760, made application to 
the Drug Enforcement Administration to be registered as an importer of 
the basic classes of controlled substances listed below:

------------------------------------------------------------------------
                    Drug                               Schedule         
------------------------------------------------------------------------
Methaqualone (2565)........................  I                          
Ibogaine (7260)............................  I                          
Tetrahydrocannabinols (7370)...............  I                          
Bufotenine (7433)..........................  I                          
Dimethyltryptamine (7435)..................  I                          
Etorphine (except HCl) (9056)..............  I                          
Methylphenidate (1724).....................  II                         
Pentobarbital (2270).......................  II                         
Diprenorphine (9058).......................  II                         
Etorphine Hydrochloride (9059).............  II                         
Diphenoxylate (9170).......................  II                         
Metazocine (9240)..........................  II                         
Methadone (9250)...........................  II                         
Fentanyl (9801)............................  II                         
------------------------------------------------------------------------

    The firm plans to import small quantities of the controlled 
substances to manufacture laboratory reference standards and 
neurochemicals.
    Any manufacturer holding, or applying for, registration as a bulk 
manufacturer of these basic classes of

[[Page 20276]]

controlled substances may file written comments on or objections to the 
application described above and may, at the same time, file a written 
request for a hearing on such application in accordance with 21 CFR 
1301.54 in such form as prescribed by 21 CFR 1316.47.
    Any such comments, objections, or requests for a hearing may be 
addressed, in quintuplicate, to the Deputy Assistant Administrator, 
Office of Diversion Control, Drug Enforcement Administration, United 
States Department of Justice, Washington, D.C. 20537, Attention: DEA 
Federal Register Representative (CCR), and must be filed no later than 
(30 days from publication).
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1311.42 (b), (c), 
(d), (e), and (f). As noted in a previous notice at 40 FR 43745-46 
(September 23, 1975), all applicants for registration to import basic 
classes of any controlled substances in Schedule I or II are and will 
continue to be required to demonstrate to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration that the requirements for such registration pursuant to 
21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42 (a), (b), (c), 
(d), (e), and (f) are satisfied.

    Dated: April 30, 1996.
Gene R. Haislip,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 96-11217 Filed 5-3-96; 8:45 am]
BILLING CODE 4410-09-M